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Study of Avidity of Antigen-Specific Antibody as a Means of
Understanding Development of Long-Term Immunological Memory
after Vibrio cholerae O1 Infection
Mohammad Murshid Alam,a Mohammad Arifuzzaman,a* Shaikh Meshbahuddin Ahmad,a M. Ismail Hosen,a Mohammad Arif Rahman,a
Rasheduzzaman Rashu,a Alaullah Sheikh,a* Edward T. Ryan,b,c,d Stephen B. Calderwood,b,c,e Firdausi Qadria
Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesha; Division of Infectious Diseases, Massachusetts General
Hospital, Boston, Massachusetts, USAb; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USAc; Department of Immunology and Infectious
Diseases, Harvard School of Public Health, Boston, Massachusetts, USAd; Department of Microbiology and Immunobiology, Harvard Medical School, Boston,
Massachusetts, USAe
The avidity of antibodies to specific antigens and the relationship of avidity to memory B cell responses to these antigens have
not been studied in patients with cholera or those receiving oral cholera vaccines. Wemeasured the avidity of antibodies to chol-
era toxin B subunit (CTB) and Vibrio choleraeO1 lipopolysaccharide (LPS) in Bangladeshi adult cholera patients (n 30), as
well as vaccinees (n 30) after administration of two doses of a killed oral cholera vaccine. We assessed antibody andmemory B
cell responses at the acute stage in patients or prior to vaccination in vaccinees and then in follow-up over a year. Both patients
and vaccinees mounted CTB-specific IgG and IgA antibodies of high avidity. Patients showed longer persistence of these anti-
bodies than vaccinees, with persistence lasting in patients up to day 270 to 360. The avidity of LPS-specific IgG and IgA antibod-
ies in patients remained elevated up to 180 days of follow-up. Vaccinees mounted highly avid LPS-specific antibodies at day 17 (3
days after the second dose of vaccine), but the avidity waned rapidly to baseline by 30 days. We examined the correlation be-
tween antigen-specific memory B cell responses and avidity indices for both antigens. We found that numbers of CTB- and LPS-
specific memory B cells significantly correlated with the avidity indices of the corresponding antibodies (P< 0.05; Spearman’s
 0.28 to 0.45). These findings suggest that antibody avidity after infection and immunization is a good correlate of the devel-
opment and maintenance of memory B cell responses to Vibrio choleraeO1 antigens.
Vibrio cholerae O1 can cause acute watery diarrhea with severedehydration in both children and adults and may lead to death
if untreated (1). Natural infection with Vibrio cholerae O1 induces
protection against subsequent symptomatic disease for at least 3 to
7 years (2, 3). Considerable efforts have been made in the last 3
decades to develop safe and effective oral cholera vaccines.
However, the currently available licensed vaccines give protec-
tion for between 2 to 3 years, shorter than that following nat-
ural infection (4, 5). Several markers of protection against
cholera on exposure, such as plasma IgA against V. cholerae O1
lipopolysaccharide (LPS) (6), vibriocidal antibodies (7, 8), and
memory B cell responses to cholera antigens (9, 10), have been
suggested as potential markers of protective immunity. How-
ever, plasma antibody responses decrease in the 6 to 9 months
after cholera, before protective immunity wanes, and while
memory B cell responses persist longer, assay of these responses
is more complicated. It would be helpful in understanding pro-
tective immunity to cholera after infection or vaccination if
there was an earlier indicator of subsequent development of
longer-term immunological memory.
In previous studies with patients, we have shown that robust
systemic and mucosal antibodies against lipopolysaccharide
(LPS), cholera toxin B subunit (CTB), and colonization factors,
including the major subunit of the toxin-coregulated pilus
(TcpA), develop after cholera and these may play a role in protec-
tion against subsequent infection (11–14). Responses against pro-
tein antigens were detectable for a longer period than responses to
the T cell-independent carbohydrate antigen LPS, suggesting that
T cells may be important for developing and maintaining memory
B cell responses (15).
Antibody avidity, the functional affinity of multivalent anti-
body to bind multivalent antigen, has been used as a marker of B
cell maturation to discriminate between primary and secondary
responses to a number of infections, including infections with
dengue virus (16), rubella virus (17), (18), cytomegalovirus (19),
and herpesvirus (20). Furthermore, antibody avidity is an impor-
tant surrogate for determining protective immunity for several
vaccines, including measles vaccine (21), Haemophilus influenzae
type b conjugate vaccine (22), pneumococcal capsular polysac-
charide vaccine (23), and mumps vaccine (24). However, studies
on avidity of antibodies generated following cholera and cholera
vaccination have not been reported to date, nor has this been
assessed for other noninvasive infections of the gastrointestinal
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tract. It is also not known if the avidity of antibody responses
correlates with the development and duration of memory B cell
responses.
In this study, we analyzed the avidity of IgG and IgA antibodies
to both a T cell-dependent antigen (CTB) and a T cell-indepen-
dent antigen (LPS) following natural cholera infection and oral
cholera vaccination, and we correlated these with the develop-
ment of memory B cell responses recognizing the same antigens.
MATERIALS AND METHODS
Study subjects and specimens. We enrolled adult cholera patients pre-
senting to the hospital of the International Centre for Diarrheal Disease
Research, Bangladesh (ICDDR,B) (9). We also enrolled healthy adults
from an urban field site in Mirpur, Dhaka, Bangladesh, who were given
two doses of the inactivated whole-cell oral cholera vaccine Dukoral at
2-week intervals (25). The healthy volunteers did not take antibiotics in
the past 2 weeks, which was a criterion for enrollment into the study.
Venous blood was collected at the time of enrollment (day 2 for patients
and day 0 for vaccinees) and 3 days after intake of each dose of vaccine;
follow-up blood samples were obtained from patients and vaccinees on
study days 30, 90, 180, 270, and 360 to measure antibody avidity responses
by enzyme-linked immunosorbent assay (ELISA). Specimens from both
the patients with cholera and following cholera vaccination (Table 1)
were used for plasma antibody avidity measurements and for analyses
of memory B cell responses to two key antigens, CTB and LPS (25). The
specimens for this analysis were obtained from Institutional Review
Board (IRB)-approved studies of the Massachusetts General Hospital
and/or ICDDR,B.
Isolation of PBMCs. Peripheral blood mononuclear cells (PBMCs)
and plasma were isolated from heparinized blood diluted with phosphate-
buffered saline (PBS) by centrifugation on Ficoll-Isopaque (Pharmacia).
Isolated PBMCs were resuspended to a concentration of 1 107 cells/ml
in RPMI complete medium (Gibco) supplemented with 10% heat-inac-
tivated fetal bovine serum (FBS) (10) and were used for the memory B cell
culture. Plasma was frozen at70°C for serologic assays.
CTB-andLPS-specific antibodies inpatients andvaccinees.Both the
IgG and IgA antibody responses were measured by ELISA using previ-
ously described procedures (14, 26). We used 96-well polystyrene plates
(Nunc F; Nunc, Denmark) coated with V. cholerae O1 Ogawa LPS for the
vaccinees (250 ng/well) and the serotype of V. cholerae O1 LPS (Inaba or
Ogawa) homologous to their infecting strain for patients. For the toxin-
specific responses, plates were coated with ganglioside GM1 (0.3 nmol/
ml), followed by recombinant CTB subunit (50 ng/well) (both gifts from
A. M. Svennerholm, University of Gothenburg, Gothenburg, Sweden).
Then, 100 l of plasma (diluted 1:100 for CTB and 1:25 for LPS in 0.1%
bovine serum albumin in phosphate-buffered saline–Tween) was added
per well, followed by horseradish peroxidase-conjugated secondary anti-
bodies to human IgG or IgA (Jackson ImmunoResearch, West Grove,
PA). Plates were developed with ortho-phenylene diamine (Sigma, St.
Louis, MO) in 0.1 M sodium citrate buffer (pH 4.5) and 0.1% hydrogen
peroxide. Each plate was read kinetically at 450 nm for 5 min; the maximal
rate of change for samples in optical density in milli-absorbance units per
minute was normalized across plates by calculating the ratio of the test
sample value to a standard of pooled convalescent-phase serum from
previously infected cholera patients included on each plate.
Plasma CTB- and LPS-specific IgG and IgA antibody avidity mea-
sured by ELISA. Avidity indices for CTB- and LPS-specific plasma IgG
and IgA antibody responses were measured as described earlier (27).
Briefly, 96-well microtiter plates (Nunc F) were coated as described above.
The plates were incubated with two pairs of serially diluted plasma sam-
ples (1:5 to 1:2,000 dilution in 0.1% bovine serum albumin–phosphate-
buffered saline–Tween) for 90 min at room temperature (RT). The super-
natants of the wells were discarded, and one pair of the wells for each
sample was treated with a chaotropic agent, sodium thiocyanate (NaSCN)
(2 M in PBS– 0.3% Tween) for 20 min at RT, whereas the other pair of
wells was treated with PBS– 0.3% Tween alone. After washing with PBS-
Tween, horseradish peroxidase-conjugated anti-human IgG or IgA anti-
bodies (Jackson Laboratories, Bar Harbor, ME) were added at a 1:1,000
dilution, and plates were developed as described above. The optical den-
sity (OD) was measured at 492 nm after addition of 1 M sulfuric acid to
the plates. For each patient sample, non-NaSCN-treated wells with an OD
of between 0.5 and 2.0 were used for the calculation of antibody avidity
(28). The avidity index (AI) was calculated as the percentage of the ratio of
measured optical density (OD) in the NaSCN-treated wells to that in the
untreated wells (27) (AI [%]OD of NaSCN-treated well 100/OD of
non-NaSCN-treated well). A positive-control specimen derived from
pooled, convalescent-phase sera from cholera patients was included on
each ELISA plate (25, 26).
Memory B cell culture and ELISPOT assay. We assessed memory B
cell responses at study initiation (days 0 and 2 in vaccinees and patients,
respectively) and on days 30, 90, 180, 270, and 360 using a previously
described method (9, 10, 29, 30). For this assay, 5  105 cells/well were
cultured in 24-well cell culture plates (BD Biosciences, San Jose, CA)
containing culture medium optimized to stimulate antigen-independent
proliferation and differentiation of memory B cells into antibody-secret-
ing cells (ASCs). The medium consisted of RPMI 1640, 10% FBS, 200 U of
penicillin/ml, 200 g of streptomycin/ml, 2 mM L-glutamine, 50 M -mer-
captoethanol, and a mixture of three B cell mitogens, i.e., CpG oligonu-
cleotide (Operon, Huntsville, AL), crude pokeweed mitogen extract, and
fixed Staphylococcus aureusCowan (Sigma). As a negative control, PBMCs
were also placed into wells containing this culture medium lacking mito-
gens. The plates were incubated at 37°C in a 5% CO2 incubator for 5 to 6
days, after which the cells were harvested and used to perform antigen-
specific (CTB and LPS) and total IgG and IgA enzyme-linked immuno-
spot (ELISPOT) assays. IgG and IgA ASCs were detected using horserad-
ish peroxidase-conjugated mouse anti-human IgG and IgA (Hybridoma
Reagent Laboratory), respectively, followed by development with 3-ami-
no-9-ethyl carbazole (AEC). ELISPOT counts were expressed as the per-
centage of antigen-specific memory B cells out of the total IgG or IgA
memory B cells in the culture. Wells coated with keyhole limpet hemocy-
anin (KLH) (Pierce Biotechnology, Rockford, IL) were used as a negative
control. Criteria for inclusion and exclusion of data for analyses were as
described previously (25).
Statistical analyses. Comparisons of the immune responses during
the 1-year follow-up were tested for significance within different study
groups using the Wilcoxon signed rank test and between groups using







Median age, yr (range) 31 (18–46) 32 (20–45)
Sex, no. (%) of subjects
Male 17 (57) 17 (57)
Female 13 (43) 13 (43)
ABO blood group, no. (%) of subjects
A 7 (23) 7 (23)
B 11 (37) 10 (33)
AB 1 (3) 1 (3)
O 11 (37) 12 (40)
Infecting Vibrio cholerae O1 serotype, no.
Ogawa 20 NAb
Inaba 10 NA
a There were no significant differences between the study groups.
b NA, not applicable.
Alam et al.
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the Mann-Whitney U test. We also used repeated-measures multivar-
iate analysis of variance (MANOVA) to determine differences between
groups. All reported P values are two sided, with a P value of 0.05
considered a threshold for statistical significance. Spearman’s correla-
tion analysis was used to measure bivariate associations. Analyses were
performed using GraphPad Prism 5.0, SigmaStat 3.1, SPSS 14.0, and
STATA 10.
RESULTS
Study population. Patients admitted to the ICDDR,B hospital
with dehydration were treated with intravenous fluid as well as
with azithromycin. For the patients, the mean duration of stay in
the hospital was 38 h. We enrolled 30 adult cholera patients, both
males (57%) and females (43%), for plasma antibody avidity mea-
surements and for analyses of correlation of avidity with memory
B cell responses to CTB and LPS. Specimens from 30 healthy adult
cholera vaccinees (57% male and 43% female) were also analyzed.
Vaccinees were disease free at the time of specimen collection.
However, during the course of the study we did not follow them
up for illnesses; they were also not admitted to the ICDDR,B di-
arrheal hospital for any disease during the study period. Details of
the patients and vaccinees are shown in Table 1; the demographic
characteristics of the patients and vaccinees in the study were
comparable. All strains of V. cholerae O1 were of the El Tor bio-
type and of the altered variant and of both Ogawa and Inaba se-
rotypes. There were no differences in the severity of diarrhea be-
tween cholera patients infected with the Ogawa or Inaba serotype
of V. cholerae O1.
CTB- and LPS-specific IgG and IgA antibodies in patients
and vaccinees. An antibody response at any time point was de-
fined as a significantly higher response than day 2 or day 0 re-
sponses for patients and vaccinees, respectively, and both Ogawa-
and Inaba-infected patients showed comparable responses (P 
0.05). Responses to both CTB and LPS were similar in patients and
vaccinees, although the anti-LPS-specific IgA responses waned
earlier in vaccinees (Fig. 1). The CTB-specific responses lasted
longer than the LPS-specific responses in both patients and vac-
cinees. This is probably because the response to the protein anti-
gen CTB is T cell dependent whereas that to LPS is T cell indepen-
dent, resulting in an immune response of shorter duration. The
IgG responses were of higher magnitude than the IgA responses.
Antibody responses peaked at day 30 in patients. In vaccinees,
significant responses were found on day 3, after the first dose of
vaccine (day 0), and these were substantially boosted at day 17,
that is 3 days after intake of the second dose of vaccine (given on
day 14), showing preexistence of CTB- and LPS-specific memory
B cells in the study individuals.
Avidity of CTB-specific antibodies in patients and in vaccin-
ees. The mean CTB-specific IgG antibody avidity index (AI) in
cholera patients on day 2 of infection was 35%  1.2%; this in-
creased significantly at day 30 (AI 48% 2.8%,P 0.0002) and
remained elevated throughout the 360 days of follow-up (Fig. 2A).
Prior to vaccination, the CTB-specific IgG AI in healthy adults was
37%  1.6%, similar to that in the acute stage in patients. There
was no change in the avidity index at 3 days after intake of the first
dose of vaccine, but the AI increased significantly by day 17
(60% 2.8%), after the second dose of vaccine; the AI decreased
gradually and reached baseline levels within 270 days of follow-up.
The CTB-specific IgG AI in patients was significantly higher than
FIG 1 CTB-specific (A and B) and LPS-specific (C and D) antibody responses in plasma in adult Bangladeshi cholera patients and in vaccine recipients who
received two doses of cholera vaccine at an interval of 2 weeks apart (day 0 and day 14, indicated by arrows). Bars indicate mean responses, and error bars
represent standard errors of the means. The Wilcoxon signed rank test was used for analyses of data. *, statistically significant difference (P  0.05) from the
baseline (day 0 or day 2) titer and the follow-up days indicated.
Avidity of Antibody to Vibrio cholerae O1
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that in vaccinees at days 270 and 360. Similarly, the CTB-specific
IgA AI remained elevated in patients up to day 270 of follow up
(AI  42%  2.3%; P  0.0352), while the AI in vaccinees re-
mained significantly elevated only out to 90 days after vaccination
(AI 46% 2.2%; P 0.0135) (Fig. 2B). Comparable responses
in the CTB-specific IgA were seen at each time point of analysis up
to day 360 (Mann-Whitney U test). However, significant differ-
ences in CTB responses were seen between the two groups (P 
0.001) using repeated-measures MANOVA.
LPS-specific avidity responses in patients and vaccinees. On
day 2 of infection, the LPS-specific IgA AI was approximately 39%
in patients; this increased significantly at day 30 (AI  49% 
2.4%; P  0.0005) and remained elevated up to day 180 postin-
fection before decreasing to baseline levels (Fig. 2D). The prevac-
cination LPS-specific IgA AI in healthy adults was 39% (day 0),
similar to that at day 2 in patients. A significantly higher LPS-
specific IgA AI (AI  48%  2.6%; P  0.0168) was detectable
only on day 17 in vaccinees but returned to baseline levels by day
30 and beyond (Fig. 2D). The LPS-specific IgA AI was significantly
higher in patients with cholera for up to 180 days following infec-
tion than the AI following two doses of vaccination in healthy
Bangladeshi adults. A similar pattern of AIs was observed for LPS-
specific IgG. The AI remained elevated up to 180 days following
infection (AI 46% 1.9%; P 0.0014) but was elevated only at
day 17 in vaccinees (Fig. 2C). Compared to that in vaccinees, the
magnitudes of the LPS-specific IgG or IgA AI in patients at days
270 and 360 were comparable, and they waned down to baseline
on these study days. Using MANOVA, a difference in the IgA but
not the IgG response was seen.
Antigen-specific IgG and IgA memory B cell responses. Sta-
tistically significant increases in CTB-specific IgG memory B cell
responses compared to the baseline responses were detected at day
30 in both cholera patients and vaccinees (P 0.05) (Fig. 3). The
CTB-specific IgA memory responses were also elevated by day 90
and day 30 in patients and vaccinees, respectively. The memory B
cell response in patients to CTB-specific IgA on day 30 was in-
creased, but this did not reach statistical significance (P 0.057),
probably due to the lower numbers of matched data points that
were available for this analysis. In patients, CTB-specific IgG
memory B cell responses persisted for up to 1 year, while the
response waned by day 270 in vaccinees. An anti-CTB-specific IgA
memory B cell response could also be seen at the later stage at day
270 in patients but not in vaccinees. Cholera patients also devel-
oped LPS-specific IgA and IgG memory B cell responses that were
significantly elevated by day 30 and day 180, respectively, although
these levels decreased by 360 days (Fig. 3). In comparison, we did
not detect any significant increases of LPS-specific IgA or IgG
memory B cell responses in the vaccine recipients at any time
point.
Correlation between antibody avidity and antigen-specific
memory B cell responses. To determine the correlation between
antibody avidity index and memory B cell responses, we com-
pared avidity indices with memory B cell responses on corre-
sponding days for each antigen and each antibody isotype in both
FIG 2 Avidity indices of CTB-specific (A and B) and LPS-specific (C and D) antibodies in plasma in Bangladeshi adult cholera patients and in vaccine recipients
who received two doses of cholera vaccine at an interval of 2 weeks (day 0 and day 14). Bars indicate mean responses, and error bars represent standard errors of
the means. The Wilcoxon signed rank test was used for analyses of data. *, statistically significant difference (P 0.05) from the baseline (day 0 or day 2) titer to
follow-up indicated above; #, statistically significant difference between cholera patients and vaccinees (P 0.05).
Alam et al.
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patients and vaccinees. Both CTB- and LPS-specific IgG and IgA
avidity indices in patients and vaccinees showed significant posi-
tive correlations with corresponding memory B cell responses
(Spearman’s 	  0.28 to 0.45; P 0.05) (Table 2).
DISCUSSION
In this study, we have shown that antibody responses following
cholera and cholera vaccination are robust and develop significant
avidity for both the T cell-dependent antigen cholera toxin and the
T cell-independent antigen lipopolysaccharide. This is the first
study that we are aware of that assesses antibody avidity following
a noninvasive mucosal infection, and we show that not only IgG
but also IgA antibodies develop significant avidity. We also show
that antibody avidity measurements correlate with memory B cell
responses to the same antigen at the same time point, consistent
with both of these responses developing in parallel during B cell
maturation following antigen exposure.
Memory B cells are a major component of antibody-mediated
long-term protective immunity following infection or vaccina-
tion. For T cell-dependent antigens, memory B cell development
and differentiation occur in germinal centers (GC) of secondary
lymphoid tissue (31). Upon exposure to an antigen, antigen-pre-
senting cells such as dendritic cells present epitopes of that antigen
to CD4
 helper T cells, leading to the differentiation of these CD4
T cells into T follicular helper cells (Tfh), which migrate into the
GC of intestinal Peyer’s patches and mesenteric lymph nodes.
These Tfh, characterized by expression of CXCR5, interact in GC
with B cells that recognize that epitope, leading to proliferation of
the B cell with somatic hypermutation and isotype switching. One
result of this proliferation and maturation is the production of
plasma cells (both short- and long-lived) of higher antibody affin-
ity after negative selection in the GC of low-affinity antibody-
producing B cells (31, 32). The other result of this proliferation
and maturation process is the generation of memory B cells that
can play a role in subsequent protective immunity (29). We have
recently shown that early T cell responses to CTB following either
cholera or cholera vaccination correlate well with subsequent
memory B cell responses, consistent with the sequential events
outlined above for maturation of the B cell responses for T cell-
dependent antigens (33). Generation of highly avid IgG antibodies
FIG 3 CTB and LPS memory B cell responses in Bangladeshi adult cholera patients and vaccinees who received two doses of cholera vaccine separated by 2 weeks
(day 0 and day 14). Memory B cell responses are expressed as percent antigen-specific responses of total isotype-specific memory B cells. Bars represent mean
responses, and error bars represent standard errors of the means. *, statistically significant difference (P  0.05) from the baseline (day 0 or day 2) titer; #,
statistically significant difference between cholera patients and vaccinees (P 0.05).
TABLE 2 Correlation analyses of antibody avidity index and memory B
cell responses in patients and vaccineesa
Comparisonb Spearman’s 	 P value
CTB specific
IgG AI and IgG MBC
Patients 0.350 0.001
Vaccinees 0.450 0.001




IgG AI and IgG MBC
Patients 0.369 0.006
Vaccinees 0.373 0.001
IgA AI and IgA MBC
Patients 0.283 0.048
Vaccinees 0.324 0.001
a Spearman’s test was used for correlation analyses.
b AI, avidity index; MBC, memory B cell response.
Avidity of Antibody to Vibrio cholerae O1
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for T cell dependent antigens has been shown previously for a
number of important systemic infections, including dengue virus,
rubella virus, and cytomegalovirus infections, as well as following
vaccination for measles, Haemophilus influenzae, and pneumo-
coccal disease (16, 17, 19, 21–23). T cell-independent antigens,
such as LPS, activate antigen-specific B cells to proliferate and
mature directly through Toll-like receptors (TLRs) or with the
help of dendritic cells (34, 35). Dendritic cells utilize a nondegra-
dative endocytic pathway to present T cell-independent antigens
to B cells, and this leads to B cell proliferation, isotype switching,
and maturation of high-affinity antibody production outside GC
and without T cell help (34, 36–39). In the lamina propria, B cell
activation leads predominantly to class switching to IgA2 (40). In
Peyer’s patches, class switching is similarly biased to the IgA iso-
type (41). Class-switched mature B cells then circulate, rehome to
mucosal surfaces, and mature into plasma cells that produce IgA
for secretion into the intestinal lumen. High-affinity, secretory
IgA antibodies at mucosal surfaces neutralize microbial toxins and
pathogens to help provide protection from disease with the help of
high-affinity IgA antibodies (42).
The mechanism of protective immunity after cholera or chol-
era vaccination is currently not fully understood. Our previous
studies suggest that protective immunity may be directed largely
to the T cell-independent antigen LPS and that the development
and particularly maintenance of memory B cells to LPS may differ
strikingly between individuals infected with V. cholerae and those
receiving a killed, oral cholera vaccine (25), potentially explaining
the relatively short-term protection conferred by current cholera
vaccination. In this study, we show that the antibody avidities of
both IgA and IgG antibodies to CTB and to LPS correlate with
memory B cell development to the same antigens, consistent with
both events occurring as a result of B cell proliferation and matu-
ration. We also show that the duration of high-affinity antibodies
to both CTB and LPS is significantly different in patients and
vaccinees, similar to the results with memory B cells.
Antibody avidity is known to be a reliable surrogate marker of
immunological memory for systemic infections (22). Several
studies have shown that both antibody avidity and the memory B
cell response are indicators of previous exposure to a pathogen.
The current protocol for measuring memory B cell responses that
we have used in our studies (9, 10) is based on polyclonal stimu-
lation of peripheral blood mononuclear cells (PBMCs) by mito-
gens for 6 days, followed by an ELISPOT procedure to estimate
spot-forming ASCs; this technique is best carried out with fresh
blood, may require substantial volumes of blood, and takes a week
to complete. Measurement of antibody avidity by ELISA, on the
other hand, is quicker, requires less blood, does not require mitogen
stimulation, can be multiplexed for multiple antigens and multiple
antibody isotypes, and can be done on stored serum or plasma sam-
ples historically collected. In this study, the correlation coefficients,
although significant, were low, but our results suggest the potential
use of the measurement of antibody avidity in plasma or serum as a
potentially useful and less expensive alternative than measurement of
memory B cell responses to predict protective immunity following
infection or vaccination, particularly in facilities with limited re-
sources and laboratory infrastructure.
In this study, the antibody avidities of two key antigens of CTB
and LPS were measured in both patients and vaccinees to deter-
mine if a correlation of protection could be found. A vibriocidal
antibody response is the current surrogate marker of protection
against V. cholerae O1 infection, which is largely associated with
anti-LPS antibody responses. Also, the level of serum IgA specific
to LPS was found to be associated with protection against cholera
(6). In this study, we showed that patients and vaccinees develop
highly avid antibodies to both CTB and LPS, although the CTB-
specific IgG or IgA antibodies with high affinity persisted for lon-
ger time period than those to LPS. It is possible that protective
efficacy studies using measurements of antibody avidity to LPS
may show some correlation in the future. This study was carried
out in a country where cholera is endemic, Bangladesh, where
infection with V. cholerae and enterotoxigenic Escherichia coli
(ETEC) is prevalent. Individuals are preexposed to the different
antigens and hence can have preexisting memory B cells. In this
study, we have seen significant increases of CTB- and LPS-specific
IgG and IgA antibody responses in vaccinated individuals on day 3
after the first dose of vaccine conferring preexisting memory B
cells in the study participants.
In summary, our results show that both cholera patients and
those receiving a killed, oral cholera vaccine develop highly avid
antibodies of both the IgG and IgA isotypes to both the T cell-
dependent antigen CTB and the T cell-independent antigen LPS
and that the avidity indices of these antibody responses correlate
well with measurement of memory B cell responses at correspond-
ing time points, suggesting that both events may be occurring as
part of B cell proliferation and maturation. Patients with cholera
have a longer duration of highly avid antibodies and of memory B
cells to both antigens, particularly to the T cell-independent anti-
gen LPS, than do individuals receiving the cholera vaccine, con-
sistent with the shorter duration of protection afforded by the
vaccine. Improved understanding of all the events leading to B cell
maturation to T cell-independent antigens in gut mucosa and the
lamina propria may provide additional insights of relevance to
improving the duration of protection obtained from current chol-
era and other mucosal vaccines. Antibody avidity may also pro-
vide a simpler and more widely available assay for measuring B cell
proliferation and maturation events after infection and vaccina-
tion than the current memory B cell assay.
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